Sandoz Group AG said on Monday it has reached an agreement to pay a total of $450 million to resolve long-running litigation in the United States that accused the company of anti-competitive practices in the generic pharmaceuticals market.
The settlement covers claims lodged by 43 U.S. states and territories related to alleged conduct involving generic medicines. Under the terms disclosed by the company, Sandoz's U.S. subsidiary will make $400 million of the payment in installments spread across seven years, with the installment schedule set to commence in 2027.
In addition to the installment plan, Sandoz will make an extra payment of about $50 million to a set of states that had previously reached separate settlement agreements with the company. Sandoz said that neither this settlement nor the payment to those earlier-settled states constitutes an admission of wrongdoing by its U.S. business.
The company also emphasized that the agreement does not change its existing financial guidance. Specifically, Sandoz stated the settlement will not alter its full-year 2026 guidance or its stated mid-term financial outlook.
The litigation resolved by this agreement is part of a wider, years-long legal effort by U.S. state attorneys general. Those state-led actions have targeted several manufacturers in the generic drug sector with allegations that companies coordinated prices and allocated customers for certain medicines.
Key context and implications
- The settlement quantifies the disputed exposure for Sandoz at $450 million in total, split between installment payments by its U.S. subsidiary and additional payments to states with prior agreements.
- The agreement explicitly includes no admission of wrongdoing and, according to Sandoz, does not change its guidance for full-year 2026 or its mid-term financial outlook.
- The matter forms part of broad, multi-state litigation targeting the generic pharmaceuticals sector over alleged price coordination and customer allocation.
Where this matters
The settlement directly affects Sandoz and its U.S. operations, and it relates to the broader generic drug industry and healthcare sector. Legal and regulatory scrutiny in the generics market also has implications for state governments that brought the claims.
Note on reporting limits
This article reports only the information released by the company and the description of the litigation as presented. It does not introduce additional facts or outcomes beyond the company's statements and the scope of the claims covered in the disclosed agreement.